Planta Med 2010; 76(16): 1820-1826
DOI: 10.1055/s-0030-1249976
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Puerarin Protects Dopaminergic Neurons against 6-Hydroxydopamine Neurotoxicity via Inhibiting Apoptosis and Upregulating Glial Cell Line-Derived Neurotrophic Factor in a Rat Model of Parkinson's Disease

Guoqi Zhu1 , 2 [*] , Xuncui Wang2 [*] , Yuefa Chen2 , Shu Yang2 , Hui Cheng2 , Ning Wang2 , Qinglin Li2
  • 1Institutes of Brain Science, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, PR China
  • 2Anhui Province Key Laboratory of R&D of Chinese Medicine, Anhui University of Traditional Chinese Medicine, Hefei, China
Further Information

Publication History

received February 2, 2010 revised April 23, 2010

accepted April 26, 2010

Publication Date:
27 May 2010 (online)


Neurodegeneration is one of the primary etiologies in the onset of Parkinson's disease. In the quest for a new antiparkinsonism treatment the potential benefits of puerarin from the roots of Pueraria lobata have been recognized. Thus, we examined whether puerarin is capable to protect dopaminergic neurons of the substantia nigra against 6-hydroxydopamine induced neuronal cell death. Our data showed that the intraperitoneal administration of 0.12 mg/kg/day puerarin over 10 days reduced the 6-hydroxydopamine-induced decrease of tyrosine hydroxylase-positive cell counts. Analysis of apoptosis via DNA fragmentation by the terminal deoxynucleotidyl transferase dUTP nick-end labeling assay proved that puerarin could prevent 6-hydroxydopamine-induced apoptosis. As an additional apoptotic cell death marker, the BAX and BCL-2 expression levels were investigated using immunohistochemistry. Whereas 6-hydroxydopamine increased the level of Bax (p < 0.05), the coadministrated puerarin significantly antagonized this effect in a dose-dependent manner. Bcl-2 expression was not affected. Analysis of the dopamine, dihydroxyphenylacetic acid, and L-dihydroxy-phenyl-alanine contents of 6-hydroxydopamine-treated animals by HPLC revealed that puerarin was capable to restore the contents of dopamine and its metabolites. Moreover, the expression level of glial cell line-derived neurotrophic factor in the striatum was higher in puerarin than in rats treated with 6-hydroxydopamine alone. These results suggest that puerarin develops its neuroprotective effect against 6-hydroxydopamine-induced neurotoxicity in the substantia nigra through the inhibition of apoptotic signaling pathways and upregulation of glial cell line-derived neurotrophic factor expression in the striatum.


  • 1 Dauer W, Przedborski S. Parkinson's disease: mechanisms and models.  Neuron. 2003;  39 889-909
  • 2 Vernier P, Moret F, Callier S, Snapyan M, Wersinger C, Sidhu A. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.  Ann NY Acad Sci. 2004;  1035 231-249
  • 3 Lev N, Melamed E, Offen D. Apoptosis and Parkinson's disease.  Prog Neuropsychopharmacol Biol Psychiatry. 2003;  27 245-250
  • 4 Schulz J, Gerhardt E. Apoptosis: its relevance to Parkinson's disease.  Clin Neurosci Res. 2001;  1 427-433
  • 5 Tomac A, Lindqvist E, Lin L F, Ogren S O, Young D, Hoffer B J, Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.  Nature. 1995;  373 335-339
  • 6 Kirik D, Georgievska B, Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease.  Nat Neurosci. 2004;  7 105-110
  • 7 Gill S S, Patel N K, Hotton G R, O'Sullivan K, McCarter R, Bunnage M, Brooks D J, Svendsen C N, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.  Nat Med. 2003;  9 589-595
  • 8 Choi-Lundberg D L, Lin Q, Chang Y N, Chiang Y L, Hay C M, Mohajeri H, Davidson B L, Bohn M C. Dopaminergic neurons protected from degeneration by GDNF gene therapy.  Science. 1997;  275 838-841
  • 9 Santini E, Heiman M, Greengard P, Valjent E, Fisone G. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.  Sci Signal. 2009;  2 36
  • 10 Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.  Exp Neurol. 2002;  175 303-317
  • 11 Truong L, Allbutt H, Kassiou M, Henderson J M. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.  Behav Brain Res. 2009;  169 1-9
  • 12 Han R M, Tian Y X, Becker E M, Andersen M L, Zhang J P, Skibsted L H. Puerarin and conjugate bases as radical scavengers and antioxidants: molecular mechanism and synergism with b-carotene.  J Agric Food Chem. 2007;  55 2384-2391
  • 13 Zhang S Y, Chen S L, Shen Y J, Yang D J, Liu X J, Sun-chi A C, Xu H X. Puerarin induces angiogenesis in myocardium of rat with myocardial infarction.  Biol Pharm Bull. 2006;  29 945-950
  • 14 Cheng Y F, Zhu G Q, Wang M, Cheng H, Zhou A, Wang N, Fang N, Wang X C, Xiao X Q, Chen Z W, Li Q L. Involvement of ubiquitin proteasome system in protective mechanisms of puerarin to MPP+-elicited apoptosis.  Neurosci Res. 2009;  63 52-58
  • 15 Flores G, Liang J J, Sierra A, Martínez-Fong D, Quirión R, Aceves J, Srivastava L K. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography.  Neuroscience. 1999;  91 549-556
  • 16 Liu H, Kishi T, Roseberry A G, Cai X, Lee C E, Montez J M, Friedman J M, Elmquist J K. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter.  J Neurosci. 2003;  23 7143-7154
  • 17 Mikhaylova M, Vakhitova J V, Yamidanov R S, Salimgareeva M K, Seredenin S B, Behnisch T. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats.  Neuropharmacology. 2007;  53 601-608
  • 18 Meng H, Li C, Feng L, Cheng B, Wu F, Wang X, Li Z, Liu S. Effects of ginkgolide B on 6-OHDA-induced apoptosis and calcium over load in cultured PC12.  Int J Dev Neurosci. 2007;  25 509-514
  • 19 Yuan W J, Yasuhara T, Shingo T, Muraoka K, Agari T, Kameda M, Uozumi T, Tajiri N, Morimoto T, Jing M, Baba T, Wang F, Leung H, Matsui T, Miyoshi Y, Date I. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons.  BMC Neurosci. 2008;  9 75
  • 20 Salakou S, Kardamakis D, Tsamandas A C, Zolota V, Apostolakis E, Tzelepi V, Papathanasopoulos P, Bonikos D S, Papapetropoulos T, Petsas T, Dougenis D. Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis.  In Vivo. 2007;  21 123-132
  • 21 Gomez-Lazaro M, Galindo M F, Concannon C G, Segura M F, Fernandez-Gomez F J, Llecha N, Comella J X, Prehn J H, Jordan J. 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p 38 MAPK-mediated, p 53-independent activation of Bax and PUMA.  Neurochemistry. 2008;  104 1599-1612
  • 22 Chen Y H, Harvey B K, Hoffman A F, Wang Y, Chiang Y H, Lupica C R. MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector.  FASEB J. 2008;  22 261-275
  • 23 Dauer W. Neurotrophic factors and Parkinson's disease: the emergence of a new player?.  Sci STKE. 2007;  411 60

1 Equal contribution to this article.

Prof. Dr. Qinglin Li

Anhui Province Key Laboratory of R&D of Chinese Medicine
Anhui University of Traditional Chinese Medicine

Meishan Road

Hefei 230038


Phone: + 86 55 15 16 90 51

Fax: + 86 55 15 16 93 71